57 results about "Sodium Deoxycholate" patented technology

The invention discloses an asiatic acid elastic self-adaptive liposome as well as a preparation method and application thereof. The betaine and the lipidosome are utilized to synergistically improve the membrane stability, permeability and binding capacity of the lipidosome, the asiatic acid lipidosome synthesized by the asiatic acid instead of cholesterol is used as a delivery carrier of the exosome to improve the skin microenvironment and increase the effective utilization rate, and the Tween 80 is utilized to reduce the membrane surface tension of the lipidosome. Meanwhile, sodium deoxycholate is adopted to enhance the electrostatic interaction between the liposome and the skin, so that the liposome can generate reversible shape change when exposed to external stimulation, and the transdermal efficiency and the stability of the liposome are improved again while certain self-adaption is achieved. Finally, a lipid nano-carrier capable of realizing exosome non-invasive efficient transdermal delivery, remodeling a skin microenvironment and treating skin related diseases is constructed. A new thought is provided for transdermal delivery and clinical application of the exosome.

A composition comprising a glucagon-like peptide 1 (GLP-1) agonist for sublingual or buccal administration, wherein the composition comprises one or more agents selected from the group consisting of; sodium glycodeoxycholate; sodium deoxycholate; carboxymethyl cellulose; sodium alginate; SNAC (salcaprozate sodium); a non-ionic ester alkoxylate (or alkanoic acid ester alkoxylate); and soy lecithin.

The application provides a topical traditional Chinese medicine composition for treating vulvar leukoplakia and a preparation method thereof. The composition is composed of traditional Chinese medicinal materials such as angelica, cortex psoraleae and barks of dictamnus dasycarpus, and a penetration enhancer, an activating agent and a moisturizing agent. The penetration enhancer is composed of soybean lecithin, phosphatidylethanolamine and cholesterol, the activating agent is sodium cholate, sodium deoxycholate and sodium taurocholate, and the moisturizing agent is eucalyptus oil. The drugs are compatible to exert the effects of clearing heat and drying dampness, cooling blood and nourishing yin, activating blood and resolving stasis, warming yang and dispelling cold and supporting healthy qi and tonifying the body resistance. The traditional Chinese medicine composition is prepared through supercritical extraction, micronization treatment, solution preparation and intermittent ultrasonic homogenization. The traditional Chinese medicinal materials are used for treating the etiology, pathogenesis and symptoms of vulvar leukoplakia, the penetration enhancer reduces the skin barrier function, the activating agent enhances the drug activity and permeability, and the moisturizing agent maintains the skin moisture and assists in anti-inflammation. The clinical application effectively relieves the symptoms of patients with vulvar leukoplakia, improves the pathological state of local skin and improves the treatment effect, thereby providing a new effective option for the treatment of vulvar leukoplakia.

The application provides a preparation method and application of a near-infrared two-region fluorescent sensor, and chiral single-walled carbon nanotubes are separated by using a double water phase extraction method; materials in the separation process include deionized water, polyethylene glycol, dextran, sodium dodecyl sulfate, sodium deoxycholate and cholic acid sodium hydrate; the chiral single-walled carbon nanotubes are dispersed and mixed with 4-nitrobenzene tetrafluoroboric acid diazonium salt to obtain the fluorescent sensor; high-purity (6,5)-SWCNT is efficiently and simply separated by using the double water phase extraction technology, the prepared SWCNT-NBD nanomaterial has good optical performance, including bright light emission in the near-infrared two-region, has good penetration capacity on biological tissues, the fluorescent detector (SWCNT-NBD) has low detection line, wide linear range, good selectivity on DA, and is convenient to prepare and low in cost.

The invention discloses a probiotic with the characteristic of high yield of bile salt hydrolase and application of the probiotic in a preparation for preventing or improving cholestatic jaundice, and is characterized in that the probiotic is at least one of a bifidobacterium longum subsp. Infantis QS033 strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.35879 and a lactobacillus delbrueckii subsp. Lactis QS021 strain with the preservation number of CGMCC No.35880; according to the present invention, the Chukrasone A has the application of the Chukrasone A in the preparation of the product for preventing, relieving or regulating the cholestatic jaundice, and has the advantages of effective degradation of sodium glycocholate, sodium glycodeoxycholate, sodium glycochenodeoxycholate and sodium glycoursodeoxycholate, effective regulation of bile acid metabolism disorder in the cholestatic jaundice, and improvement of the cholestatic jaundice.

The invention provides a rain wash resistant and long-acting antibacterial liquid-liquid condensed phase and a preparation method and application thereof.The liquid-liquid condensed phase comprises polyethyleneimine, sodium deoxycholate and metal chloride salt, the concentration of the polyethyleneimine is 0.5 g / L-5 g / L, and the molecular weight of the polyethyleneimine is 600-25000; the concentration of the sodium deoxycholate is 0.5 mM to 50 mM.

Disclosed are a pharmaceutical composition, an aprepitant injection, and an aprepitant freeze-dried powder injection. The pharmaceutical composition comprises aprepitant, a primary stabilizer, and a secondary stabilizer, wherein the primary stabilizer comprises sodium deoxycholate and the secondary stabilizer comprises povidone. The aprepitant injection can be administered by injecting. The formulation uses a largely reduced amount of excipients, and is less irritative to an injection site, less prone to cause a hypersensitive reaction, and thus safer when being used by a patient. The formulation has good stability and can be stored and transported at room temperature, largely reducing production, storage, and transportation costs.

The application provides a kind of antibiotic-loaded nanoemulsion and its preparation method and application, it is related to the technical field of medical adjuvant, antibiotic is mixed with medicinal adjuvant soybean oil, dipalmitoyl phosphatidylcholine and cholesterol, and volatile organic solvent is used to dissolve and form oil phase;Deoxycholic acid sodium and tween are dissolved in sterile liquid to form water phase;Oil phase and water phase are mixed, and are treated by ultrasonic treatment, rotary evaporation treatment and high pressure homogenization treatment, to obtain antibiotic-loaded nanoemulsion.The application adjusts the type of inhalable medicinal adjuvant, the addition ratio of inhalable medicinal adjuvant, the ratio of oil phase and water phase, and the ultrasonic power and homogenization pressure and other factors, so that the prepared nanoemulsion can efficiently load antibiotic, and has good aerosol inhalation performance, better drug stability, the nanoemulsion can be retained in mouse lung tissue for a long time, and the lung drug delivery efficiency is significantly improved.

This invention relates to a midazolam nanocrystal suspension, which, by weight-volume percentage, comprises 5%–45% midazolam, 1%–10% Tween, and 0.1%–10% sodium deoxycholate (SDC). The midazolam nanocrystal suspension of this invention exhibits superior blood-brain barrier permeability and bioavailability, making it suitable for needle-free injection administration.

The invention relates to the technical field of medicines, and provides a semeglutide coated tablet and a preparation method thereof. The chip-coated sheet comprises a chip core layer and a shell layer, the tablet core layer comprises a first absorption enhancer; the shell layer comprises a second absorption enhancer; the first absorption enhancer and the second absorption enhancer are selected from the group consisting of sodium 8-(2-hydroxybenzamido) caprylate, Tween 80, lauryl sodium sulfate, sodium caprate, polyglycerol-3 diisostearate, oleic acid, lauric acid, sodium deoxycholate, sodium cholate, polyoxyethylene (35) castor oil, PEG-vitamin E succinate, PEG-vitamin D3 succinate and pluronic. The invention relates to a preservative which is prepared from the following raw materials: polyethylene glycol, a methoxy polyethylene glycol-polycaprolactone copolymer, sucrose fatty acid ester, 15-hydroxystearic acid polyethylene glycol ester and caprylic / capric acid polyethylene glycol glyceride. The coated tablet provided by the invention adopts a double-layer structure consisting of the tablet core layer and the shell layer, so that the bioavailability of the preparation can be remarkably improved, the oral dosage can be hopefully and greatly reduced, and the medication cost is reduced.

The invention discloses a brain-targeted nasal-spray amphotericin B phospholipid complex and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the brain-targeted nasal-spray amphotericin B phospholipid complex is prepared by adopting a film dispersion method, and the preparation method comprises the following steps: dissolving 15-hydroxystearic acid polyethylene glycol ester, phospholipid, cholesterol, amphotericin B and optional other auxiliary components in a solvent, removing the solvent until a film is formed, and drying to obtain the brain-targeted nasal-spray amphotericin B phospholipid complex. And carrying out hydration dispersion to obtain the amphotericin B-loaded phospholipid complex. According to the amphotericin B sodium deoxycholate injection, the problems that the traditional amphotericin B sodium deoxycholate injection is high in renal toxicity, the intrathecal injection is poor in solubility, and low in bioavailability and patient compliance, large in side effect and the like due to the fact that the traditional amphotericin B sodium deoxycholate injection is difficult to penetrate through a blood brain After nasal administration, the drug is quickly delivered into the brain, so that the slow release of the drug is realized, the intracerebral bioavailability of the drug is improved, high brain targeting and low systemic toxic and side effects are realized, and good clinical application value and market prospect are achieved.

The invention discloses a single-walled carbon nanotube magnetic purification method and a single-walled carbon nanotube magnetic purification device. Efficient purification is realized through the synergistic effect of high-temperature oxidation and gradient magnetic field technologies. The method comprises the following steps: carrying out thermal oxidation pretreatment on a single-walled carbon nanotube in a mixed atmosphere of nitrogen and synthetic air at 450 DEG C, removing amorphous carbon and exposing metal impurities; dispersing the oxidized single-walled carbon nanotubes in a 1% sodium deoxycholate or sodium dodecyl benzene sulfonate solution; two-stage magnetic treatment is adopted, in the first stage, an N48 neodymium magnet array rotary reactor is used for removing strong magnetic impurities, and in the second stage, a nanotube aggregate is further separated through an N42 neodymium magnet annular cavity. The device comprises a reaction chamber, a magnet array and a motor system, the energy consumption is as low as 15 mW, and the metal impurity removal rate is greater than 97%. The method overcomes the defects of high energy consumption of a traditional centrifugal method and structural damage of an acidification method, is suitable for the single-walled carbon nanotubes prepared by various processes such as HiPco, CoMoCAT and the like, and has the potential of high efficiency, environmental protection and industrial application.

The invention discloses a suspension liquid. The suspension comprises brexpiprazole or a salt thereof, a suspending aid and a surfactant, wherein the surfactant is selected from the group consisting of Tween 20; and at least one of span, poloxamer, lauryl sodium sulfate and sodium deoxycholate. By adopting the surfactant, the suspension can be prevented from generating precipitates after being placed for a long time, and the particle size of the brexpiprazole or the salt of the brexpiprazole can be ensured to be within 10 microns after the brexpiprazole or the salt of the brexpiprazole is placed for one month; the suspension can be rapidly released after being injected into an animal body, achieves an effective treatment level, is continuously and slowly released to maintain the effective treatment level for 30 days or more, has good pharmacokinetic properties, and can solve the problem of patient compliance to the greatest extent. The suspension provided by the invention has the advantages of lasting drug effect, accurate particle size control, high stability, good pharmacokinetic property and the like.

The invention discloses a polyamide reverse osmosis membrane with a high rejection rate and a preparation method thereof, and relates to the technical field of membrane separation. The preparation method comprises the following steps: selecting a polyether sulfone ultrafiltration base membrane as a supporting layer to ensure the basic characteristics of higher mechanical strength and chemical resistance, carrying out pretreatment on a lauryl sodium sulfate solution, N, N, N-trimethyl chitosan and sodium deoxycholate to enhance the hydrophilicity and provide active sites for forming polyamide by interfacial polymerization, and adding a surfactant into a water-phase solution to improve the mechanical strength and chemical resistance of the membrane. The preparation method comprises the following steps: adding an amine monomer into an oil phase solution, accelerating the diffusion rate of the amine monomer in an interfacial polymerization reaction, adding modified silicon dioxide into the oil phase solution, forming a stable organic silicon grafting layer on the surface of nano silicon dioxide, grafting tert-butylhydroquinone on the surface of nano silicon dioxide, reducing the attack of chlorine on a polyamide chain, and improving the chlorine resistance of the polyamide chain; the rejection rate of the polyamide reverse osmosis membrane on salt inorganic matters is improved by regulating and controlling surface charges of the base membrane, activating an interface and introducing an anti-chlorine group.

The present application relates to a curcumin nanocrystal composition, the composition contains 1-18% (m / v) of curcumin nanocrystal, 0.1-10% (m / v) of stabilizer, 0.1-10% (m / v) of surfactant and 0-10% (m / v) of suspending agent in mass volume percentage, wherein the particle size of the curcumin nanocrystal is less than or equal to 100 nm, the stabilizer is selected from any one or combination of hydroxypropyl methyl cellulose (HPMC), polyvinylpyrrolidone PVPK12PF, polyvinylpyrrolidone PVPK15, polyvinylpyrrolidone PVPK17PF, lecithin, polyethylene glycol, poloxamer Pluronics F68, poloxamer Pluronics F108, the surfactant is selected from any one or combination of sodium cholate, sodium deoxycholate, sodium docusate, sodium dodecyl sulfate (SDS), sodium dodecyl sulfonate (SLS), sodium alginate, and the suspending agent is selected from any one or combination of sucrose, dextran, glycerol, povidone, hydroxypropyl cellulose, methyl cellulose, hypromellose, sodium carboxymethyl cellulose, carboxymethyl cellulose, polyvinyl alcohol, gum arabic, dextrin. The composition of the present application has the advantages of fast onset, good stability, high bioavailability, safety and effectiveness.

The invention discloses a co-amorphous system for improving water solubility of dihydromyricetin and a preparation method thereof, the co-amorphous system comprises dihydromyricetin and a hydrophilic component according to a molar ratio of (2-1): (1-3), the hydrophilic component is chlorogenic acid, sodium taurine deoxycholate or disodium glycyrrhizinate, and the co-amorphous system is prepared by a reduced pressure evaporation method; the preparation method comprises the following steps: adding a solvent into dihydromyricetin and a hydrophilic component according to a certain proportion, dissolving, carrying out ultrasonic treatment to a clear state, then putting into a water bath at 50-70 DEG C, and carrying out rotary evaporation on the solvent under reduced pressure to obtain the dihydromyricetin-hydrophilic component co-amorphous system. The co-amorphous system prepared by the invention has the characteristic of improving the water solubility and stability of dihydromyricetin.

The invention discloses a screening culture medium and a preparation method and application thereof, the screening culture medium comprises a basic culture medium and additives, and the additives comprise amphotericin B, vancomycin, ox bile salt, sodium deoxycholate and No.3 bile salt. According to the screening culture medium provided by the invention, a special infectious microbe inhibitor is added on the basis of a trisaccharide iron culture medium, so that most gram-negative enterobacter, staphylococcus aureus and part of fungi except salmonella enteritis subspecies and shigella cannot grow; the interference of the infectious microbes on the detection of the salmonella enteritis subspecies and the shigella is avoided, so that the fluorescent probe can be applied to the detection of the salmonella enteritis subspecies and the shigella in a clinical anus swab, and the sensitivity of color development is improved.

The present invention discloses an enzymatic digestion method for gently reducing agent to digest tissue samples and its mass spectrometry detection method. The present invention provides a lysis solution, which comprises: a detergent with a final concentration of 1-4% by mass fraction; the detergent is sodium deoxycholate and / or ammonium bicarbonate; 3-(2-carboxy)phosphine hydrochloride with a final concentration of 5-20 μM; 5-chloro-anthranilic acid with a final concentration of 20-60 mM; tris(hydroxymethyl)aminomethane-hydrochloride with a final concentration of 50-200 mM; phenylmethylsulfonyl fluoride with a final concentration of 0.1-2 mM; and water. After the tissue samples are lysed with the lysis solution of the present invention, tissue proteins and peptides can be obtained with a high yield.

The present application provides a method for separating single chiral carbon nanotube mirror bodies, comprising the following steps: (1) dispersing carbon nanotube raw materials into a solution of a composite surfactant to obtain a carbon nanotube dispersion liquid; (2) using gel chromatography for stepwise elution to separate the carbon nanotube dispersion liquid, and collecting the separation product to obtain single chiral carbon nanotube mirror bodies; wherein the solution of the composite surfactant comprises cholic acid, a first surfactant and an optional second surfactant, and a solvent; the first surfactant is selected from one or more of sodium octyl sulfate, sodium decyl sulfate, sodium dodecyl sulfate and sodium n-hexadecyl sulfate; the second surfactant is selected from one or more of sodium cholate, sodium hydrate cholate, sodium dehydrocholate, sodium deoxycholate, sodium lithocholate, sodium hyodeoxycholate and sodium chenodeoxycholate. The method of the present application can separate and prepare single chiral carbon nanotube mirror bodies with a diameter of less than 0.69 nanometers.

The present disclosure relates to a pharmaceutical composition of a JAK kinase inhibitor. Specifically, the invention provides a pharmaceutical composition, which comprises an active component (3aR, 5s, 6aS)-N-(3-methoxy-1, 2, 4-thiadiazole-5-yl)-5-(methyl (7H-pyrrolo [2, 3-d] pyrimidine-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-formamide or a pharmaceutically acceptable salt thereof, and an anionic surfactant, and the active component (3aR, 5s, 6aS)-N-(3-methoxy-1, 2, 4-thiadiazole-5-yl)-5-(methyl (7H-pyrrolo [2, 3-d] pyrimidine-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-formamide or a pharmaceutically acceptable salt thereof, the anionic surfactant is selected from at least one of lauryl sodium sulfate and sodium deoxycholate. The pharmaceutical composition can improve the solubility of the active ingredients, the content of impurities in the finished product is low, and the pharmaceutical composition has good stability and meets the quality requirements of oral preparations.

The present invention discloses a low-molecular-weight local anesthetic gel, liposomes, and preparation methods thereof. The raw materials of the low-molecular-weight local anesthetic gel include: a local anesthetic, a bile salt, an aqueous solvent, or a buffer; the local anesthetic is selected from an amide local anesthetic; and the bile salt is selected from at least one of sodium cholate, sodium deoxycholate, sodium chenodeoxycholate, sodium lithocholic acid, sodium ursocholic acid, sodium ursodeoxycholate, sodium glycodeoxycholate, sodium taurolithocholic acid, sodium glycotaurocholate, sodium glycochenodeoxycholate, sodium phenylpropanecholate, sodium casocholic acid, sodium leukocholic acid, bile acid dimer, bile acid side chain amino acid conjugate, bile acid side chain PEG conjugate, and bile acid side chain glucose conjugate. The preparation process of the gel and liposome of the present invention is simple and controllable, and can achieve the purpose of postoperative pain management after a single administration.

The application discloses a kind of DOC-Chaps synergistic core's clinical and animal tissue rapid transparent reagent and three-dimensional imaging method. Rapid transparent reagent is mainly dissolved in deionized water by sodium deoxycholate (DOC), 3-[(3-cholamide propyl) dimethylamino]-1-propane sulfonic acid (Chaps), urea and 1-methylimidazole; DOC efficiently dissolves high-density lipid, Chaps gently destroys membrane structure, both complement each other, realize lipid rapid, depth clearance and significantly reduce light scattering; urea loosens collagen fiber and protein aggregate, improves the penetration rate of reagent; 1-methylimidazole selectively removes hemoglobin, reduces light absorption. The transparent reagent of the application can make millimeter thick brain slices in 4 (mouse brain) / 6 (human brain) hours The light transmittance of specific wavelength is greater than or equal to 90%, and there is no obvious tissue shrinkage / expansion, the compatibility of fluorescent protein and antibody label is excellent, suitable for three-dimensional imaging of high-lipid, high-hemoglobin samples such as in-vitro human brain, kidney, liver and mouse brain, heart, kidney, liver, intestinal tract, embryo, etc.

The invention provides a silicon-carbon nanowire negative electrode material, a preparation method and application of the silicon-carbon nanowire negative electrode material in a lithium ion battery, and belongs to the technical field of silicon-carbon materials. According to the invention, sodium deoxycholate, Zn (NO3) 2.6 H2O and 2-methylimidazole are mixed and reacted to prepare a hollow linear carbon framework material, and then the hollow linear carbon framework material is sequentially subjected to internal silicon nanowire deposition and surface carbon coating to obtain the silicon-carbon nanowire negative electrode material. The silicon nanowire disclosed by the invention shows a remarkable anti-pulverization characteristic; meanwhile, the hollow linear carbon framework material effectively isolates direct contact between electrolyte and the silicon nanowires, and lithium ion irreversible loss caused by repeated generation and damage of an SEI film is reduced, so that the attenuation rate of the battery capacity is slowed down, and the cycle performance is improved.

The application discloses a clinical biochemical composite quality control product, which comprises detection item raw materials, a matrix liquid and a protective agent; the detection item raw materials are alkaline phosphatase, amylase, sodium glycocholate, cholinesterase, creatinine, leucine aminopeptidase, lactate dehydrogenase, lipase, triglyceride, cholesterol, uric acid, urea, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, glucose, alpha-hydroxybutyric acid dehydrogenase, sodium hydrogen phosphate, magnesium chloride, calcium chloride, ferrous chloride, bilirubin, pancreatic amylase and sodium bicarbonate; the matrix liquid is bovine serum albumin and human serum albumin; and the protective agent is dithiothreitol (DTT), mannitol, trehalose, sodium chloride, a composite enzyme stabilizer AES and sodium azide. The quality control product can realize the detection of 27 clinical biochemical items, and the freeze-drying process is adopted, so that the freeze-dried composite quality control product has low viscosity, is easy to be re-dissolved and mixed, has high stability and has small matrix effect.

The invention relates to the technical field of medicine, in particular to an icaritin-sodium taurodeoxycholate co-amorphous substance and a preparation method and application thereof.In the icaritin-sodium taurodeoxycholate composition, icaritin serves as a main active ingredient, sodium taurodeoxycholate serves as a potential biological surfactant, and the icaritin-sodium taurodeoxycholate co-amorphous substance has the advantages that the icaritin-sodium taurodeoxycholate co-amorphous substance can be used for preparing an anti-inflammatory drug; wherein the molar ratio of icaritin to sodium taurodeoxycholate is (1: 0.5)-(1: 5), preferably (1: 1)-(1: 2). According to the icaritin-taurodeoxycholic acid sodium co-amorphous substance disclosed by the invention, the dissolving property and the dissolution property of icaritin can be remarkably improved, and the problem that the solubility and the dissolution rate of icaritin are low is solved; under the same dosage, the icaritin-sodium taurodeoxycholate co-amorphous substance has better tumor inhibition effect and oral bioavailability than icaritin.

A composition comprising a glucagon-like peptide 1 (GLP-1) agonist for sublingual or buccal administration, wherein the composition comprises one or more agents selected from the group consisting of; sodium glycodeoxycholate; sodium deoxycholate; carboxymethyl cellulose; sodium alginate; SNAC (salcaprozate sodium); a non-ionic ester alkoxylate (or alkanoic acid ester alkoxylate); and soy lecithin.

The present invention discloses a cell lysate, an enzyme activity detection kit for cells and applications thereof. The components of the cell lysate include: a first buffer, an isotonic component, Triton X-100, sodium deoxycholate, EDTA, BSA, sucrose, glycerol, β-cyclodextrin, mannitol, hexose, sodium carboxymethyl cellulose, sodium sulfate, dextran, PVP, glycine, PEG6000. The cell lysate of the present invention removes the ionic detergent component SDS, avoiding the denaturation and inactivation of the enzymes released by cell lysis due to the strong denaturing effect of SDS. At the same time, the combination of Triton X-100 and sodium deoxycholate can meet the requirement of destroying cell membranes and organelle membranes. On the other hand, β-cyclodextrin, sodium carboxymethyl cellulose, dextran, etc. that protect enzyme activity are added to protect the stability of the enzymes released by cells after cell lysis and the enzyme structure in the kit. The cell lysate of the present invention is suitable for the detection of enzyme activity in cells, reducing the difficulty of sample processing.

The application provides a method for improving the linear range of a latex-enhanced turbidimetry kit and the latex-enhanced turbidimetry kit, and relates to the technical field of analysis and detection. The application finds that sodium deoxycholate is added to reagent 1 of the existing latex-enhanced turbidimetry kit. Experimental verification shows that the correlation coefficient of the existing latex-enhanced turbidimetry kit can be effectively improved, and the upper limit of the detection linearity of the latex-enhanced turbidimetry kit is improved to 500 mg / L, thereby effectively alleviating the problem that the linear range of the reagent of the existing latex-enhanced turbidimetry kit is narrow, and 90% of the sample amount in the clinic cannot be covered, so as to affect the accuracy of the clinical detection result.

The invention discloses a selective culture medium and method for screening or separating aeromonas, and relates to the technical field of microbial culture. The selective culture medium comprises a yeast extract, a nitrogen source, a carbon source, sodium citrate, sodium deoxycholate, sodium thiosulfate, ferric citrate, sodium chloride, agar, an acid-base indicator, ampicillin and diaminopteridine. The method can be used for rapidly and efficiently separating the aeromonas, and provides reliable preposition selection for detection or identification of the aeromonas.

The present application improves the precipitation degree of the protein to be tested by changing the concentration of the sodium deoxycholate solution, thereby improving the accuracy of the determination of the protein adsorption rate in the pneumococcal polysaccharide protein conjugate vaccine. At the same time, the present application determines that the protein content is within the range of 60μg / ml to 90μg / ml, which can minimize the impact of the protein content determination diluent on the protein content determination, and make the protein recovery rate between 95% and 105%. The method for determining the protein content in the pneumococcal polysaccharide protein conjugate of the present application has the characteristics of high accuracy and high stability. Compared with the traditional Lowry method, the results are more reliable and can be widely used in the determination of the protein adsorption rate in the pneumococcal polysaccharide protein conjugate vaccine.